In:
Blood, American Society of Hematology, Vol. 124, No. 2 ( 2014-07-10), p. 263-272
Abstract:
MLL-AF6 leads to aberrant activation of RAS and its downstream targets. RAS targeting is a novel potential therapeutic strategy in AML patients carrying t(6;11).
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-09-525741
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2014
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7